Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 223

The DOI matches its Crossref record.

A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia–reperfusion injury

Open access
Fiordaliso, Fabio, Chimenti, Stefano, Staszewsky, Lidia, Bai, Antonio, Carlo, Eleonora, Cuccovillo, Ivan, Doni, Mirko, Mengozzi, Manuela, Tonelli, Rossella, Ghezzi, Pietro, Coleman, Thomas, Brines, Michael, Cerami, Anthony, Latini, Roberto · 2005 · Proceedings of the National Academy of Sciences

Abstract

The cytokine erythropoietin (EPO) protects the heart from ischemic injury, in part by preventing apoptosis. However, EPO administration can also raise the hemoglobin concentration, which, by increasing oxygen delivery, confounds assignment of cause and effect. The availability of EPO analogs that do not bind to the dimeric EPO receptor and lack erythropoietic activity, e.g., carbamylated EPO (CEPO), provides an opportunity to determine whether EPO possesses direct cardioprotective activity. In vivo , cardiomyocyte loss after experimental myocardial infarction (MI) of rats (40 min of occlusion with reperfusion) was reduced from ≈57% in MI-control to ≈45% in animals that were administered CEPO daily for 1 week (50 μg/kg of body weight s.c.) with the first dose administered intravenously 5 min before reperfusion. CEPO did not increase the hematocrit, yet it prevented increases in left ventricular (LV) end-diastolic pressure, reduced LV wall stress in systole and diastole, and improved LV response to dobutamine infusion compared with vehicle-treated animals. In agreement with the cardioprotective effect observed in vivo , staurosporine-induced apoptosis of adult rat or mouse cardiomyocytes in vitro was also significantly attenuated (≈35%) by CEPO, which is comparable with the effect of EPO. These data indicate that prevention of cardiomyocyte apoptosis, in the absence of an increase in hemoglobin concentration, explains EPO's cardioprotection. Nonerythropoietic derivatives such as CEPO, devoid of the undesirable effects of EPO, e.g., thrombogenesis, could represent safer and more effective alternatives for treatment of cardiovascular diseases, such as MI and heart failure. Furthermore, these findings expand the activity spectrum of CEPO to tissues outside the nervous system.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.0409329102

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Metadata

Authors
Fiordaliso, F., Chimenti, S., Staszewsky, L., Bai, A., Carlo, E., Cuccovillo, I., Doni, M., Mengozzi, M., Tonelli, R., Ghezzi, P., Coleman, T., Brines, M., Cerami, A., & Latini, R.
Venue
Proceedings of the National Academy of Sciences
Published
2005-01-25
Volume
102
Issue
6
Pages
2046-2051
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W2068624628
Cited by
223
References
0
FWCI
16.06
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia–reperfusion injury. https://app.cochat.ai/papers/10.1073/pnas.0409329102
The paper
Fiordaliso, F., Chimenti, S., Staszewsky, L., Bai, A., Carlo, E., Cuccovillo, I., Doni, M., Mengozzi, M., Tonelli, R., Ghezzi, P., Coleman, T., Brines, M., Cerami, A., & Latini, R. (2005). A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia–reperfusion injury. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.0409329102

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.